EPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
EUPRAXIA PHARMACEUTICALS INC.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 13, 2026
$6.95+0.33 (+4.98%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.17 (+20.24%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
EUPRAXIA PHARMACEUTICALS INC. reported revenue of $0 for fiscal 2025.
Revenue
$0
FY2025
EPS, diluted
-$1.03
FY2025
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$38.58M
- EPS, diluted
- -$1.03
Five years at a glance
Fiscal years 2021 to 2025, USD
Revenue
$0
Net income
-$38.58M
EPS, diluted
-$1.03
Reported period